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Introduction:
Prostate cancer is among the most frequently diagnosed cancers and the second most common cause of male cancer-related death (1, 2). It arises through a progression from an initial benign stage to frank malignancy, most often correlating with androgen-dependence and then androgen-independence in the late stage (3) . Among genetic changes accompanying prostate cancer, of greatest interest are genetic "hits" in prostate epithelial cells that might represent initiating events for oncogenesis or consistent somatic mutations that specifically affect these cells. Identification of and modeling these causal genetic alterations would be invaluable in providing novel therapeutic targets and prognostic markers. Recently, chromosomal rearrangements between androgenresponsive genes, such as TMPRSS2, and genes encoding the ETS family transcription factors (ERG, ETV1, ETV4, and ETV5) were identified in >50% of prostate cancer cases (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Due to their high incidence in prostate cancer, these may represent the most common gene rearrangements identified in human cancers. In addition, in analogy to the role of translocations in hematological malignancies, these chromosomal rearrangements represent either the initiating event in oncogenesis or a critical and consistent set in the cancer progression. Among ETS genes involved in these rearrangements, the most common one is ERG, followed by ETV1 (14) . Arrangements of coding regions of these ETS genes to control regions of androgen-responsive genes presumably lead to overexpression of these proto-oncogenes. In this study, we plan to create and characterize a series of mouse models based on TMPRSS2-ERG (or ETV1) gene rearrangements to study roles of these ETS genes, especially ERG, in development and in prostate tumorigenesis. We also plan to use biochemical approaches to identify downstream targets of ERG as well as its interaction partners. These studies would allow us to develop preclinical animal models, and to identify and validate novel therapeutic targets, for treating prostate cancer.
Body:

Specific aim 1: Establish a novel Cre/lox conditional knockin mouse model of prostate cancer based on the newly identified TMPRSS2-ERG(or ETV1) gene arrangements.
We proposed to use the Cre/lox conditional approach to model prostate cancer based on the TMPRSS2-ERG/ETV1 chromosomal rearrangements. We planned to use two different strategies to achieve this aim. In one strategy, we proposed to generate conditional knockin alleles to express the N-terminal truncated human ERG (or ETV1, as found in patients) from the mouse endogenous Tmprss2 locus. In a second strategy, we proposed to create knockin alleles of both Tmprss2 and Erg by introducing a single loxP site to each allele, which would then permit Cre-mediated interchromosomal recombination as well as intrachromosomal excision.
For the first strategy, we knocked in the N-terminus-truncated human ERG or ETV1 cDNA together with an iresGfp marker into the exon 2 of mouse Tmprss2 locus. We placed a transcriptional stopper cassette together with Neo (Neo-ST) upstream of the knockin cDNA. The Neo-ST cassette is flanked by loxP sites. Cre-mediated excision would remove this cassette and activate the Tmprss2-ERG or ETV1 fusion genes. Several correctly targeted independent ES clones from either ERG or ETV1 knockins were injected into mouse blastocysts and a colony of germline-transmitted heterozygous knockin mice was established. In addition, we also generated several stopper-removed knockin Tmprss2-ERG ES cell lines in vitro and made chimeric male mice from them by blastocysts injection. Since in these male chimeras, Tmprss2-ERG has already been activated in prostate cells carrying this allele, we have started to monitor them for any prostate abnormality. By RT-PCR, we confirmed that the Tmprss2-ERG fusion transcript was expressed from the endogenous Tmprss2 locus from prostate tissues of the Tmprss2-ERG chimeric males (Figure 1 ), suggesting the human ERG cDNA was indeed correctly targeted to the mouse Tmprss2 locus.
For the second strategy, we aimed to introduce a single loxP site to both the Tmprss2 and the Erg loci, respectively. If the two knockin loxP sites are located on the same chromosome (chromosome 16 for mice), Cremediated recombination would delete the ~3Mb region between them, and generate the Tmprss2-Erg fusion gene following deletion. If the two loxP sites are knocked into two different chromosome 16s, then Cre-medicated recombination would lead to chromosomal translocation. The Tmprss2-Erg fusion gene would be created following translocation. To generate such a model, we first introduced the above-described floxed Neo-ST cassette into the Erg locus in the intron upstream of its exon 4. This immediately gave us a knockdown allele for Erg, which would allow us to study the role of Erg in normal development (will discuss in the progress for specific aim 2). In ES cells carrying this Erg knockdown (kd) allele, we expressed Cre transiently in vitro to remove the floxed Neo-ST cassette. After excision, only a single loxP site remains. We then performed sequential targeting from these ES cells to introduce the second loxP site into the Tmprss2 locus. This was also achieved through the introduction of the floxed Neo-ST cassette, followed by the Cre-mediated removal of this cassette. Currently, we have obtained several positive ES clones from the sequential targeting. We are now in the process of characterizing these ES clones (confirming targeting, karyotyping, ascertaining whether two targeting events occurred on the same chromosome 16, or two different 16s).
To test a potential synergy between Tmprss2-ERG or ETV1 fusion models and other mouse models of prostate cancer, we recently acquired Pten conditional knockout mice (15) and have started to breed this strain to our Tmprss2-ERG knockin mice. Both the Pten conditional allele and the Tmprss2-ERG conditional allele would be activated by breeding in the prostate-specific PB-Cre4 transgene (16) .
Future work would focus on characterization of the Tmprss2-ERG (or ETV1) knockin mice and determine if male mice carrying these alleles (after Cre-mediated activation) would develop hyperplasia or tumors either alone or in combination with Pten loss.
Specific aim 2: Explore roles of the ETS family transcription factor ERG in development and in normal prostate by making a conditional knockout allele of this gene in mouse.
As mentioned above, we generated an Erg knockdown allele in mice by placing a transcriptional stopper cassette into the Erg locus. Mice homozygous for this knockdown allele died before E11.5 during embryonic development. At E10.5, homozygous embryos appeared pale and there was only a trace amount of blood running in major vessels, suggesting a possible endothelial cell defect, or hematopoietic defect, or both ( Figure 2 ). Since the stopper cassette we introduced is flanked by loxP site, Cre-mediated excision of this stopper cassette would allow us to restore Erg expression. We are currently breeding this Erg knockdown allele with Tie2-Cre (17) , so that we can restore Erg expression in both endothelial and blood cells during development. This would potentially allow us to bypass the early lethality we saw in Erg knockdown homozygotes. If Tie2-Cre mediated rescue would allow homozygous mice to survive to adulthood, it would allow us to study the role of Erg in prostate development, since Tie2-Cre only restores Erg expression in endothelial and hematopoietic cells, not in prostate epithelial cells.
In addition, we are in the process of making an Erg conditional knockout allele by flanking its last coding exon with loxP sites. This last exon encodes the DNA binding domain of Erg which is critical for its function. For the first targeting vector we generated based on this design, we were not able to get any correctly targeted ES clones after screened several hundred clones, suggesting a genomic region very difficult to target. We then modified this original targeting vector by extending its 3' homologous arm. After screening another several hundred ES clones, recently we obtained one clone that appeared correctly targeted at the 5' arm as determined by southern blot. Currently we are working on confirming this potential clone by testing its 3' arm by southern blot.
Specific aim 3: Identify downstream target genes of ERG or ETV1 in human prostate cancer cell lines carrying these gene arrangements using the ChIP-on-Chip approach.
To identify new ERG and ETV1 target genes and collaborating factors in prostate development and disease, we used LNCaP and VCaP prostate cancer cell lines. LNCaP cells overexpress ETV1 under the HNRPA2B1 prostate-specific promoter (12 ) , whereas VCaP cells are characterized by the presence of the TMPRSS2-ERG fusion protein (9) . Both prostate cancer cell lines displayed high ERG (VCaP) and ETV1 (LNCaP) levels that increased after androgen stimulation.
Expressing profiling by microarrays has become a standard method to study cancer. To analyze further the role of ERG and ETV1 in the prostate, we have performed siRNA-silencing experiments. Eight and 48 hours after transient transfection with ERG and ETV1 specific siRNA from Dharmacon, LNCaP and VCaP cells were harvested. We hybridized total RNA prepared from androgen stimulated ERG and ETV1 siRNA silenced experiments onto Affymetrix human whole genome expression array U133Plus2.0 in the DFCI Gene Expression Core. From the recently obtained array data, we may see a signature of self-renewal genes or signaling pathway genes, which are crucial in prostate cancer biology. We are also interested in cell migration and invasion genes, since they play a pivotal role in cancer progression.
Moreover, to identify potential target genes of ERG and ETV1 in prostate cancer, we planned to perform genome wide location analysis for mapping the in vivo ERG and ETV1 binding (or target) sites in normal and cancer cell lines. A key requirement for the success of this analysis is a reliable antibody that recognizes the protein of interest specifically in an immunoprecipitation assay. We tested several commercially available antibodies against human ERG and ETV1, and unfortunately they are not good for the process. Thus, to identify ERG and ETV1 binding sites, we utilized a metabolic biotin labeling approach (18, 19) , in which the ERG and ETV1 cDNA were engineered to contain an amino-terminal Flag epitope and a short peptide tag that serves as a substrate for in vivo biotinylation. This cDNA was then expressed in LNCaP, and VCaP cells (which were isolated from metastasic prostate cancer) previously engineered to ectopically express the Escherichia coli biotin ligase BirA. The exceptionally strong interaction between biotin and streptavidin allows for the efficient recovery of biotinylated protein with cross-linked DNA, as in conventional chromatin immunoprecipitation (ChIP) experiments. In this period, we generated LNCaP and VCaP cells that contain the bioERG and bioETV1, joined to biotin ligase BirA by retroviral infection. In the near future, material recovered in this "bio-ChIP" method will be hybridized to Affymetrix promoter arrays to identify putative target genes of ERG or ETV1. This approach (bio-ChIP-on-Chip) has been successfully utilized in our lab to identify target genes of pluripotency genes in embryonic stem cells (18) . By coupling ChIP-on-Chip information with the transcriptome analysis, we will identify candidate target genes of ERG and ETV1, which will be then validated by RT-PCR and ChIP assays. In addition, data comparing prostate normal and cancer cells will allow us to identify genetic/epigenetic changes involved in cancer initiation and progression.
Key research accomplishments:
• Successfully generated Tmprss2-ERG or ETV1 knockin mice expressing truncated human ERG or ETV1 from the endogenous mouse Tmprss2 locus.
• Generated a rescuable Erg knockdown allele in mice that would allow us to study roles of Erg during embryonic development and in prostate.
• Generated Flag-tagged biotinylated ERG or ETV1 (bioERG and bioETV1) for biochemical studies.
Reportable outcomes:
None
Conclusion:
We planned to use both a series of mouse models and biochemical approaches to study the mechanisms of pathogenesis in human prostate cancer with TMPRSS2-ERG (or ETV1) gene fusions. During the first year of this award, we have made significant progress, including successfully generating the conditional knockin mice carrying the Tmprss2-ERG (or ETV1) fusion allele, generation and initial characterization of an Erg knockdown allele, and establishment of a biotinylation system for both ERG and ETV1 in human prostate cancer cell lines for biochemical studies. Further studies using these animal and cell culture models would allow us to develop preclinical animal models, as well as to identify and validate novel therapeutic targets, for treating prostate cancer. 
